Methylophiopogonanone A, an Ophiopogon homoisoflavonoid, alleviates high-fat diet-induced hyperlipidemia: assessment of its potential mechanism

Abstract

Methylophiopogonanone A (MO-A), a homoisoflavonoid extracted from Ophiopogon japonicus, has been shown to attenuate myocardial apoptosis and improve cerebral ischemia/reperfusion injury. However, the hypolipidemic effects remain unknown. This study was performed to investigate a potential hypolipidemic effect of MO-A in hyperlipidemia rats, as well as its underlying mechanism of action. A rat model of hyperlipidemia was induced by a high-fat diet (HFD). Animals were randomly divided into three groups (n=8/group): normal control group (NC), HFD group, and HFD+MO-A (10 mg Á kg-1 Á d-1) treatment group. The effects of MO-A on serum lipids, body weight, activity of lipoprotein metabolism enzyme, and gene expression of lipid metabolism were evaluated in HFD-induced rats. In HFD-induced rats, pretreatment with MO-A decreased the body weight gain and reduced serum and hepatic lipid levels. In addition, pretreatment with MO-A improved the activities of lipoprotein lipase and hepatic lipase in serum and liver, down-regulated mRNA expression of acetyl CoA carboxylase and sterol regulatory elementbinding protein 1c, and up-regulated mRNA expression of low-density lipoprotein receptor and peroxisome proliferator-activated receptor a in the liver. Our results indicated that MO-A showed strong ability to ameliorate the hyperlipidemia in HFD-induced rats. MO-A might be a potential candidate for prevention of overweight and dyslipidemia induced by HFD.

Delphinidin-3-sambubioside from Hibiscus sabdariffa. L attenuates hyperlipidemia in high fat diet-induced obese rats and oleic acid-induced steatosis in HepG2 cells

“…At the end of the experiment, rat feces were collected, lyophilized, and weighted. Then, the feces were crushed and about 0.4 g of powder was ultrasonically extracted with 20 mL of chloroform/methanol (2:1, v/v) for 0.5 h. Finally, we collected the supernatant and fecal lipids were obtained using the vacuum drying method [ 13 ].…”

Liriopogons (Genera Ophiopogon and Liriope, Asparagaceae): A Critical Review of the Phytochemical and Pharmacological Research

“…Pretreatment with MO-A (10 mg/kg), a homoisoflavonoid, significantly ameliorated the hyperlipidemia in rats induced by high fat diet HFD through regulating the serum lipid profile by modulating the expression levels involved in lipogenesis and lipid oxidation, i.e., inducing the expression levels of both low-density lipoprotein receptor (LDLR) and peroxisome proliferators-activated receptors (PPAR) α, and suppressing the expression levels of both acetyl CoA carboxylase (ACC) and sterol regulatory element-binding protein 1c (SREBP-1C) ( Li et al, 2020 ).…”

Methylophiopogonanone A is a naturally occurring broad‐spectrum inhibitor against human UDP‐glucuronosyltransferases: Inhibition behaviours and implication in herb‐drug interactions

“…Ophiopogonis Radix (also termed Maidong in Chinese), the root of Ophiopogon japonicus, is one of the most frequently used Chinese Medicine for thousands of years. 1 In East Asian nations, Ophiopogonis Radix has been widely used as a functional food ingredient or a key material for preparing some health care products and famous herbal formulations, such as Mai-Dong Soup, Sheng-Mai-Yin decoction and Shenmai injection. [2][3][4] Currently, more than a dozen of Ophiopogonis Radix prepared health care products, herbal medicines and beverages have been marketed in China, for alleviating fatigue and for preventing a variety of disorders, such as coronary heart disease, thrombosis, myocardial ischemia, arrhythmias and oesophageal carcinoma.…”

“…2,9 In the past few decades, modern pharmacological studies have demonstrated that MOA held a variety of pharmacological effects, including anti-oxidative, anti-inflammatory, anti-tumour, anti-hyperlipidemia effects and the potentials for attenuating myocardial apoptosis and improving cerebral ischemia/reperfusion injury. 1,8,10,11 These pharmacological effects of MOA have aroused great interest in the development of this agent as a drug candidate for the treatment of cardio-cerebrovascular diseases and various types of cancer. 1,8,10 Although the pharmacological activities of MOA and Ophiopogonis Radix have been extensively studied, the potential risks of MOA to trigger HDIs and the fundamental mechanism have not been well studied.…”

“…1,8,10,11 These pharmacological effects of MOA have aroused great interest in the development of this agent as a drug candidate for the treatment of cardio-cerebrovascular diseases and various types of cancer. 1,8,10 Although the pharmacological activities of MOA and Ophiopogonis Radix have been extensively studied, the potential risks of MOA to trigger HDIs and the fundamental mechanism have not been well studied. More recently, we reported that the methylenedioxyphenyl moiety of MOA could be activated by several cytochrome P450 enzymes (CYPs), which, in turn, inactivated CYP2E1 and CYP2D6 and thereby brought undesirable time-dependent inhibition of these two CYPs.…”